Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 28, 2015 5:17 PM ET


Company Overview of X-Chem, Inc.

Company Overview

X-Chem, Inc. operates as a subsidiary of Pharmaceutical Product Development Inc.

100 Beaver Street Suite 101

Waltham, MA 02453

United States





Key Executives for X-Chem, Inc.

X-Chem, Inc. does not have any Key Executives recorded.

X-Chem, Inc. Key Developments

X-Chem, Inc. Enters into Licensing Agreement with Navitor Pharmaceuticals, Inc

X-Chem, Inc. has entered into a licensing agreement with Navitor Pharmaceuticals, Inc. for an exclusive license to a series of small molecules targeting the activation of mTORC1, a protein complex that orchestrates nutrient-mediated cellular metabolism and growth. The compounds licensed by Navitor were discovered by X-Chem screening their proprietary DEX platform against protein targets supplied by Navitor under a drug discovery agreement established by the parties in 2014. X-Chem has received research funding from Navitor upon initiation of the agreement and a license fee upon exercise of the license.

X-Chem Licenses Cardiovascular Drug Discovery Program to Bayer Pharma AG

X-Chem, Inc. announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012. The latest program comprises several series of small molecule compounds against a cardiovascular drug target. Under the terms of this agreement, X-Chem will receive an upfront license fee in addition to payments based on the achievement of defined pre-clinical, clinical and sales milestones, as well as royalties. This license further validates the innovative nature of X-Chem’s team and approach.

X-Chem Signs Drug Discovery Collaboration with Alexion

X-Chem has signed drug discovery collaboration with Alexion. The contract has been signed for new therapies to treat patients with severe and ultra-rare disorders. According to the agreement, X-Chem will deploy its drug discovery engine, which is based on an ultra-large, high-diversity library in excess of 100 billion molecules, to identify new drug candidates against targets chosen by Alexion. The contract will see X-Chem receive an upfront payment and receive additional payments upon the achievement of specified research, development and regulatory milestones. X-Chem will also receive royalty payments on the sale of products resulting from the collaboration.

Similar Private Companies By Industry

Company Name Region
Breethe, Inc. United States
Amber BioLife, Inc. United States
Primordial Genetics Inc. United States
EY Laboratories, Inc. United States
Sentient Bioscience, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact X-Chem, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at